GENUS ONCOLOGY - THE MUC1-C COMPANY
  • Company
    • Mission
    • About Us
    • Genus Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Clinical and Research Partners
    • Contact
    • Sitemap
  • Why Target MUC1-C?
  • Clinical Trials
    • Summary
    • GO-203
    • Phase 2 AML Clinical Trial
  • The Science
    • Overview
    • MUC1 in Human Cancer: The Numbers
    • MUC1 in Human Cancer: Overexpression
    • Target for Carcinoma Stem-Like Cell
    • Target for Leukemia Stem Cell
    • MUC1-C is an Attractive Target for Reversing Immune Evasion
    • Intellectual Property
  • Programs
    • Pipeline
    • Targeting the Cytoplasmic Domain
    • Targeting the Extracellular Domain
    • Biomarker Program
  • News & Publications
    • News
    • Publications >
      • Complete Listing
      • Role of MUC1-C in Signal Transduction
      • Role of MUC1-C in Epigenetic Regulation
      • Role of MUC1-C in Immune Evasion
      • MUC1 Vaccine
      • MUC1-C in Stem-like Cells
      • MUC1-C inhibitor formulated in Nanoparticles
      • MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
      • MUC1-C is a druggable target

News

Studies published in “Oncogene” demonstrate that MUC1-C regulates DNA methylation in human carcinoma cells

5/23/2016

 
​These highly novel findings are important in that targeting MUC1-C represents an approach for the epigenetic reprogramming of human cancer.
DETAILS

Genus appoints Drs. Helen Sabzevari to Scientific Advisory Board

4/13/2016

 
​Genus announces the appointment of key opinion leaders Drs. Helen Sabzevari, former head of Immunotherapy at EMD and Ralph Weichselbaum, Professor at University of Chicago, as members of the Genus Scientific Advisory Board.

Genus Oncology collaborates with leukemia research leaders on new trial for AML patients

4/6/2016

 
​Genus Oncology collaborates with leaders in leukemia research at Harvard’s Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center on an investigator-initiated Phase 1b/2a trial of GO-203 in combination with Decitabine for the treatment of patients with relapsed/refractory AML.

Genus Oncology completes enrollment to Phase 1b dose escalation study of GO-203 for the treatment of relapsed/refractory AML

3/16/2016

 
​Genus Oncology completes enrollment to Phase 1b dose escalation study of GO-203 for the treatment of relapsed/refractory AML.

Study in "Cancer Research" supports targeting MUC1-C to suppress MYC expression and attenuate lung cancer growth

3/9/2016

 
​Targeting of MUC1-C suppresses MYC expression and attenuates malignant growth in KRAS mutant lung cancer.  Study published in “Cancer Research”.  These findings demonstrate that targeting MUC1-C is a novel approach for downregulating MYC expression in MYC-dependent carcinomas.
DETAILS

Studies published in “Blood” demonstrate that MUC1-C drives MYC expression in multiple myeloma

2/17/2016

 
​Studies published in “Blood” demonstrate that MUC1-C drives MYC expression in multiple myeloma.  These findings are of importance in that GO-203 treatment represents a novel therapeutic approach to target MYC in multiple myeloma cells that are addicted to MYC for their growth and survival.
DETAILS

Genus receives orphan drug designation from the US FDA for GO-203 treatment of relapsed/refractory Acute Myeloid Leukemia (AML)

11/11/2015

 
​Genus receives orphan drug designation from the US FDA for GO-203 treatment of relapsed/refractory Acute Myeloid Leukemia (AML).

Preclinical results define approach for GO-203 administration in novel nanoparticles to target MUC1-C in human cancers

5/13/2015

 
​Preclinical results of MUC1-C-targeted GO-203/nanoparticles published in the journal “Clinical Cancer Research”.  These findings define an approach for sustained administration of GO-203 in novel polymeric tetra block nanoparticles to target MUC1-C in human cancers.
Forward>>

    RSS Feed

    Archives

    December 2017
    July 2017
    May 2017
    March 2017
    February 2017
    November 2016
    September 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    November 2015
    May 2015

Company

About Us
Management
Board of Directors
​Contact
​
Sitemap

Science

MUC1-C
Why Target?
MUC1-C in Stem Cells
Publications

Programs

Targeting
Biomarker
Intellectual Property

Pipeline

Pipeline
​Clinical Trials

News

News
​Publications
© COPYRIGHT 2020 ALL RIGHTS RESERVED.
  • Company
    • Mission
    • About Us
    • Genus Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Clinical and Research Partners
    • Contact
    • Sitemap
  • Why Target MUC1-C?
  • Clinical Trials
    • Summary
    • GO-203
    • Phase 2 AML Clinical Trial
  • The Science
    • Overview
    • MUC1 in Human Cancer: The Numbers
    • MUC1 in Human Cancer: Overexpression
    • Target for Carcinoma Stem-Like Cell
    • Target for Leukemia Stem Cell
    • MUC1-C is an Attractive Target for Reversing Immune Evasion
    • Intellectual Property
  • Programs
    • Pipeline
    • Targeting the Cytoplasmic Domain
    • Targeting the Extracellular Domain
    • Biomarker Program
  • News & Publications
    • News
    • Publications >
      • Complete Listing
      • Role of MUC1-C in Signal Transduction
      • Role of MUC1-C in Epigenetic Regulation
      • Role of MUC1-C in Immune Evasion
      • MUC1 Vaccine
      • MUC1-C in Stem-like Cells
      • MUC1-C inhibitor formulated in Nanoparticles
      • MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
      • MUC1-C is a druggable target